Speaker Profile

SVP, Diagnostics Business, Personalis

Biography
Chris Hall joined Personalis in October 2022 as Senior Vice President and Head, Diagnostics Business. As part of the executive leadership team, Hall drives the vision and strategy for commercializing the company’s diagnostic product offerings. Hall brings over 20 years of experience in general management and product development within the diagnostics industry, most recently as CEO of Naring Health, Inc. Previously, he served as President, COO, and Chief Commercial Officer at Veracyte, Inc., where he led the company’s commercial entry into endocrinology and pulmonology and scaled its operational groups. Hall also served as SVP and Chief Business Officer at Berkeley HeartLab, Inc. (part of Celera Corporation), where he helped a new product launch and restructured operations to improve profitability and streamline delivery of services. Hall holds a BA in political science and economics from DePauw University and an MBA from Harvard Business School.


Clinical Dx Showcase:
Personalis

Personalis is transforming the active management of cancer through more personalized testing. With industry-leading products combining tumor-and-normal profiling with proprietary algorithms, you can detect recurrence at the earliest timepoints, confidently select therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development.

It’s Personal: The NeXT Generation of LBx
Personalis is redefining precision oncology through more personalized tumor-informed assays.

 Session Abstract – PMWC 2023 Silicon Valley

Showcase Track S2 - January 25 9.00 A.M.-1.15 P.M.,Showcase Track S2 - January 26 9.00 A.M.-1.15 P.M.,Showcase Track S1 - January 27 11.15 A.M.-3.00 P.M.


The PMWC 2023 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

  • Clinical Dx/Oncology (including Liquid Biopsy)
  • Clinical Dx/Cardio Vascular
  • Clinical Dx/Nerodegenerative